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Abstract 
Bacterial drug resistance is a worldwide problem threatening millions of lives. Several 
studies showed that bacteria develop direct resistance against an antibiotic compound used 
throughout treatment. However, recent studies demonstrated that resistance to one 
antibiotic can pleiotropically lead to resistance to other antibiotics, a concept known as 
cross-resistance, imposing serious limitations for combating against infectious diseases. 
Therefore, slowing down evolution of cross-resistance is critical and important task for 
developing effective antibiotic therapies. Despite its importance, mechanisms behind cross-
resistance are not well understood due to lack of systematic studies. Here in this systematic 
study, we aim to provide a better understanding of evolution of antibiotic resistance using 
state of the art genetic tools. In this study, we evolved 88 initially isogenic Escherichia coli 
populations against 22 different antibiotics for 21 days. For each drug, two populations 
were evolved under strong selection and two populations were evolved under mild 
selection. Representative clones from each evolved population were phenotyped against all 
22 drugs we used in our experiments and their resistance levels were carefully quantified. 
Furthermore, these clones were genotyped by Illumina whole genome sequencing and 
resistance-conferring mutations were identified.  Bacterial populations evolved under 
strong selection acquired stronger resistance against higher number of antibiotics compared 
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to populations evolved under mild selection. Strongly selected populations also acquired 
higher number of mutations compared mildly selected populations and there mutations 
were found to be more pathway specific among strongly selected populations. Finally, 
populations evolved against aminoglycosides were found to develop hypersensitivity 
against several other antibiotic classes due to mutations in trkH gene, coding for a 
membrane protein. Our study provides a thorough understanding for phenotype to genotype 
in the context of antibiotic resistance and demonstrates that selection strength is an 
important parameter contributing to the complexity of evolution of antibiotic resistance.    
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Özet 
 
Bakteri direnci dünyada çapında sağlığını tehdit eden önemli bir sorundur. Bir çok çalışma 
bakterilerin tedavi esnasında maruz kaldığı ilaca karşı direnç kazandığını ispatlamıştır. 
Ancak yeni çalışmalar bakteri hücrelerinin bir antibiyotiğe direnç kazanırken, daha önce 
maruz kalmadığı başka antibiyotiklere karşı da direnç kazandığını ispatlamıştır. Çapraz 
direnç denen bu soruna çözüm bulmak günümüzde önemli bir hal almıştır. Bu konuda bir 
çok çalışma yapılsa dahi sistematik çalışmaların yetersizliğinden ötürü çapraz direncin 
mekanizması yeterince bilinmemektedir. Bu sistematik çalışma genotipik ve fenotipik 
bulgularıyla çapraz direnç mekanizmasının daha iyi anlaşılmasını sağlayacaktır. Genetikleri 
tamamen aynı (izojenik) 88 Escherichia Coli hücresi 22 farklı ilaca 21 gün boyunca maruz 
bıraktırılarak direnç kazandırıldı. Her ilaç için iki hücreye yüksek miktarda ilaç verilip 
kuvvetli seçilimle, iki hücreye daha az miktarda ilaç verilip zayıf seçilimle direnç 
kazandırılarak iki farklı seçilim denenmiştir. Direnç kazanan hücrelere fenotip analizi 
yapılmış ve diğer ilaçlara karşı direnç seviyelerine bakılmıştır. Ayrıca dirençli hücrelerin 
tamamının genetik analizi Illumina tüm genom dizilimi ile yapılmıştır. Sonuçlar 
göstermiştir ki kuvvetli seçilimle direnç kazanan hücreler daha kuvvetli çapraz direnç 
kazanırken, zayıf seçilimle direnç kazanan hücreler daha zayıf çapraz direnç kazanmıştır. 
Aynı şekilde kuvvetli dirençle seçilen hücrelerdeki mutasyon sayısı daha fazla olup, 
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mutasyon yolundaki mutasyon sayısı yine zayıf seçilimle direnç kazananlardan daha 
fazladır. Bu çalışmanın bir diğer önemli bulgusu aminoglikozit sınıfına direnç kazanan 
bakterilerin diğer bütün ilaç gruplarına karşı çapraz hassaslık kazanmasıdır. Aynı çapraz 
direnç gibi, aminoglikozite dirençli bakteriler hiç direnç kazanmamış bakterilere kıyasla 
daha düşük ilaç konsantrasyonlarında ölebilmektedir. Bunun sebebi olarak da trkH 
genindeki mutasyon tespit edilmiştir. Bu çalışma antibiyotik direncinin genetik sebeplerinin 
fenotipik özelliklere etkisini göstererek antibiyotik direncinin anlaşılması açısından önemli 
olup, seçilimin antibiyotik direncini etkileyen önemli bir faktör olduğunu ortaya 
koymuştur.  
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1 Introduction 
Shortly after the introduction of the first antibiotic penicillin, antibiotic resistance became a 
problem for human health (Levy and Marshall 2004). It is still a major health problem and 
we still do not have a permanent and effective solution to overcome it (Gootz 2010).  
In 1940’s Penicillin became available for medical use and in 1967, penicillin resistant 
bacteria - Streptococcus pneumoniae was observed in Australia. (Davies and Davies 2010). 
Antibiotic resistance is development of a defense mechanism by the bacterium to evade the 
activity of a drug which once it was susceptible to(Davies and Davies 2010). Once the 
microbes become resistant to an antibiotic, it becomes more difficult to inhibit bacteria with 
the regular drug dose. In some cases bacteria develop resistance to more than one 
antibiotics, which are called multidrug resistant bacteria (Nikaido 2009).  
Antibiotic resistance is a natural process, which is a part of the natural selection of 
evolution. When bacteria are exposed to an antibiotic, their survival instincts try to find a 
way to thrive within the environmental stress of the antibiotics(Martinez, et al. 2009; 
Davies and Davies 2010). They develop some genetically changes that help them to 
survive, grow in the presence of antibiotics and pass this ability to their progeny (Davies 
and Davies 2010).  
In order to overcome bacterial drug resistance mechanisms, different approaches are 
developed. Using a synergistic drug combination is one of the most commonly used 
method which uses more than one drug to work together and allow the antimicrobial effect 
to take place(Chait, et al. 2007; Cokol, et al. 2011).  
Major and most important cause of the acquired antibiotic resistance is repeated exposure 
to antibiotics. Repeated antibiotic exposure can take place in hospitals, where multi-drug 
resistant strains are mostly seen, and it can also take place in outpatient circumstances due 
to over the counter availability of antimicrobial agents(Lee, et al. 2013).  
 2 
1.1 Antibiotics 
Antibiotics are chemicals that are either kills or inhibits bacteria (Kunin 1978). Antibiotics 
that kill bacteria are called bactericidal, and antibiotics that inhibit bacteria growth are 
called bacteriostatic(Pankey and Sabath 2004).  
According to their mechanism of action there are four major antibiotic classes. These are 
protein synthesis inhibitors, DNA/RNA repair inhibitors, cell wall biosynthesis inhibitors, 
and folic acid synthesis inhibitors (Cuddy 1997). 
According to specific targets of antibiotics, they have been branched in the classes. 
 
Figure 1-1: Major Antibiotic Classes and their target mechanisms. (Miesel, et al. 2003) 
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1.1.1 Cell Wall Biosynthesis Inhibitors  
Cell wall biosynthesis inhibitors (β Lactams) are mostly bactericidal antibiotics and they 
inhibit synthesis of peptidoglycan layer of bacterial cell wall. Peptidoglycan layer is 
important for bacterial division; it protects bacteria from lysis, osmotic or mechanical 
damage, as well as it takes part in bacterial pathogenicity(Ghooi and Thatte 1995). β 
Lactam Antibiotics binds Penicillin Binding Protein (PBP) in bacteria, and then inhibit cell 
wall biosynthesis. PBP is an important protein for synthesis of peptidoglycan layer. 
Inhibition of this protein leads to defective cell wall synthesis, loss of selective 
permeability and eventual cell death and lysis(Ghooi and Thatte 1995).  
β Lactams have two main groups:penicillins and cephalosporins. Bacitracin and 
Vancomycin also inhibits bacterial cell wall biosynthesis.  
Penicillin, ampicillin, penicillin G, penicillin V,amoxicillin, ticarcillin, mezlocillin, 
piperacillin,  and carbenicillin are belongs the class of penicillins(Demain 1991).  
Cephalosporins are semi synthetic antibiotics, have many members and affect both gram-
negative and gram-positive bacteria(Tune and Fravert 1980).  
In this study, we used ampicillin, piperacillin and cefoxitin antibiotics to inhibit bacterial 
growth.  
 
Figure 1-2: Structure of β Lactams. (A) Ampicillin, (B) Piperacillin, (C) Cefoxitin 
  
A B C 
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1.1.2 Protein Synthesis Inhibitors 
 
Protein synthesis inhibitors contain so many different antibiotics and each can exert their 
effects in different stages of protein synthesis (Coutsogeorgopoulos, et al. 1975). In this 
study we worked with 3 main groups of this class: 30 S robosomal subunit inhibitors, 50 S 
ribosomal subunit inhibitors and aminoglycosides. 
30S ribosomal subunit inhibitors act via binding to 30 S ribosomal subunits resulting in 
inhibition of aminoacyl-tRNA - mRNA/ribosome complex binding. We used tetracycline, 
doxycycline and spectinomycin from this class.  
 
 
Figure 1-3: Structure of 30 S inhibitors. (A) Tetracycline (B) Doxycycline (C) 
Spectinomycin. 
 
Aminoglycosides inhibit the protein synthesis via interfering with the elongation of peptide 
on 30S subunit (Tanaka 1986). We used amikacin, tobramycin, streptomycin and 
kanamycin from this class. 
A B C 
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Figure 1-4: Structure of 30S Inhibitors. (A) Amikacin (B) Tobramycin (C) Streptomycin 
(D) Kanamycin. 
 
50 S inhibitors inhibit bacterial growth by binding 50 S ribosomal subunit and inhibiting 
peptidyltransferase. We used chloramphenicol, clindamycin, erythromycin, spiramycin and 
fusidic acid from this class.  
 
Chloramphenicol is one of the important antibiotics because of its wide spectrum(Jardetzky 
1963).  
Erythromycin is member of sub group macrolides. In order to inhibit protein synthesis, they 
prevent elongation of peptide chain(Tanaka, et al. 1973).  
D C 
B A 
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Figure 1-5: Structure of 50S inhibitors. (A) Chloramphenicol (B) Clindamycin (C) 
Erythromycin (D) Fusidic Acid 
 
1.1.3 DNA/RNA Synthesis Inhibitors 
 
Nucleic acid synthesis inhibitors can either inhibit DNA replication or RNA 
transcription(Chatterji, et al. 2001). Different antimicrobial from this class have different 
mechanisms of action. For example some of antimicrobials such as rifampicin binds 
enzyme that help transcription and stop RNA synthesis(Trnka 1969). Quinolones binds 
enzyme in DNA synthesis and prevent coiling of DNA strands(Fabrega, et al. 2009).  
D 
B 
C 
A 
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Figure 1-6: Structures of DNA/RNA Synthesis Inhibitors. (A) Ciprofloxacin (B) 
Lomefloxacin (C) Nalidixic Acid. 
 
In this study we used ciprofloxacin, nalidixic acid and lomefloxacin from this class.  
 
1.1.4 Folic Acid Synthesis Inhibitors 
 
Antifolates are inhibits folic acid synthesis that is necessary for bacteria synthesis of amino 
acid. Hence inhibition of folate results inhibition of protein synthesis, DNA/RNA synthesis 
and cell division(Burchall 1973; Bodey, et al. 1982). 
 
Many of the drugs in that class are dihydrofolatereductase inhibitors (DHFR). DHFR 
inhibitors are also used in cancer treatments.  In this project, we used trimethoprim, 
sulfamethoxazole and sulfamonomethoxine (Bodey, Grose, & Keating, 1982).  
 
Figure 1-7: Folic Acid Synthesis Inhibitors. (A) Trimethoprim (B) Sulfamethoxazole 
C B A 
A B 
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1.2 Antibiotic Resistance 
 
Antibiotic resistance is defined as ability to cope with the inhibitory effects of an antibiotic 
by the bacterium(Davies and Davies 2010). Some bacteria are naturally resistant to certain 
types of antibiotics; but mostly with repeated exposure, they become resistant to antibiotics 
by mutations, acquiring resistance genes from its surroundings. 
 
Antibiotic resistance is one of the major health related problems in modern world. More 
bacteria are gaining resistance due to overuse of antibiotics(Lee, Cho, Jeong, & Lee, 2013). 
It is especially a serious problem in prolonged hospitalizations, since the bacteria are 
constantly exposed to antibiotics and the resistant strains cause serious infections. 
 
As demonstrated inHata! Başvuru kaynağı bulunamadı.Bacteria bacterial evolution may 
depend on environmental stress. When the population exposed to a stress factor such as 
antibiotics, resistant ones survive and proliferate(Martinez, et al. 2007).  
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 Figure 1-8: Bacterial evolution of drug resistance. In population antibiotic sensitive 
bacteria (green) dominates population in the absence of antibiotics (1). In presence of 
antibiotics, antibiotic sensitive wilt type bacteria growth will be inhibited and resistant 
bacteria (red) survive and proliferate (2) (3). When antibiotics are removed, bacteria may 
loose its resistance mechanism completely (1) or some bacteria may still have the 
mechanism and some of them loose (4) in order to growth better. (Martinez, et al. 2007) 
1.2.1 Mechanisms of Antibiotic Resistance 
 
There are two general types of antibiotic resistance: intrinsic and acquired (Tenover, 2006). 
Intrinsic resistance refers to bacteria’s natural ability to neutralize toxic effects of the 
antibiotic(Cox and Wright 2013). Naturally resistance in bacteria established by being 
inaccessible to the drug, being able to efflux the internalized drug via pumping 
mechanisms, lacking the target cellular elements for the drug to exert its effects, naturally 
occurring enzymes that inactivate the drug(Tenover 2006; Cox and Wright 2013). For 
example, bacteria that lack mycolic acids are intrinsically resistant to isoniazid, or 
anaerobic bacteria are resistant to aminoglycosides, which require oxidative metabolism to 
enter the cell. 
 
 10 
Acquired resistance refers to gaining ability to an antimicrobial drug, which the bacteria 
were susceptible to (Tenover, 2006). Acquiring the ability of non-preexisting resistance can 
be via mutation of bacterial chromosome, obtaining foreign genetic material that contains 
resistance genes or combination of both. Sensitive bacteria are dead when exposed to 
antimicrobial agent. But some of the bacteria successfully develops a resistance mechanism 
and lives on to pass those resistance genes to its progeny, which is called vertical gene 
transfer(Martinez, et al. 2009; Davies and Davies 2010). Bacteria also are able to perform 
horizontal gene transfer, which means acquiring genetic material outside of the bacterium 
itself. It can be classified in three ways by source of genetic material: bacterial 
transformation (uptake of genetic material from the environment, which mostly belongs to 
dead bacteria), transduction (uptake of genetic material from a bacteriophage) and 
conjugation (transfer of genetic material via sexual pilus between two bacteria)(Martinez, et 
al. 2009; Davies and Davies 2010). 
According to mechanism of action, there are four pathways of antibiotic resistance: 
prevention of the antimicrobial agent to reach its target, expulsion of the antimicrobial via 
efflux pumps, inactivation of the drug via modification or degradation, modification of 
antimicrobial target within the bacteria (Figure 1-9). 
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Figure 1-9: Mechanisms of drug resistance in bacteria. (Encyclopædia Britannica Online. 
Web. 29 May. 2014.) 
1.2.2 Cross-resistance and Multi Drug Resistant Bacteria 
 
Since antibiotic resistance become serious public health problem in the world, scientist 
used alternative antibiotics for treatment. However with this approach, scientist realize new 
and probably worse problem about drug resistance, which is cross-resistance(Sanders 
2001). In 2010 Kohanski made that observation on developing cross-resistance against 
antimicrobial drugs to which bacteria have never been exposed before(Kohanski, et al. 
2010). By helping sequencing now we can make assumption on which changes caused 
cross-resistance. Kohanski suggests that mutation in multidrug efflux pumps reason of the 
cross-resistance(Kohanski, et al. 2010). Even though this observation is true, this is not the 
only reason behind cross-resistance. Cross-resistance can be result of very different gene 
mutation. In this study we revealed different genes responsible for cross-resistance, even 
cross sensitivity.  
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As a result of cross-resistance multiple drug resistant (MDR) bacteria has been aroused. 
Commonly known MDR bacteria are methicillin resistant Staphylococcus aureus (MRSA), 
Vancomycin-Resistant Enterococci (VRE) and multi drug resistant tuberculosis. Those 
super bug causes death in many cases(Rice 2007).  
 
In this study, by exposing antibiotic to bacteria, we produced MDR Escherichia Coli and 
revealed genetic changes that cause this.  
1.2.3 Minimize Antibiotic Resistance 
 
There are many different strategies suggested to minimize antibiotic resistance. Since the 
first antibiotic has been discovered, antibiotics used as a treatment worldwide. However not 
every patients and every physicians are educated enough to know how to use 
antibiotics(Baquero and Negri 1997; Lee, et al. 2013). Wrong usage of antibiotics is 
considered one of the important reasons of antibiotic resistance. Appropriate prescribing 
antibiotic is very important to slow sown antibiotic resistance(Lee, et al. 2013). Educating 
the patient is also important since physician cannot control the patient all the time(Lee, et 
al. 2013). 
Studies showed that inappropriate prescription cause rapid increase of antibiotic 
resistance(Nathwani and Davey 1999). 
 
Development of novel antibiotics is also a way to kill resistant bacteria. Development of 
new antimicrobial agents is very straightforward way to reduce resistance however bacteria 
can be resistant eventually even before the new agent released to market(Silver and Bostian 
1993). Because of this problem, companies are not willing to invest for this method(Coates 
and Hu 2007).  
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Using synergistic drug pair is another suggestion to cope with resistant bacteria. Synergy of 
antibiotics definition is combination of two antibiotics is significantly more effective then 
one alone(Yeh, et al. 2006; Bollenbach, et al. 2009; Yeh, et al. 2009; Cokol, et al. 2011). 
Using synergistic drug pair can be effective on drug resistant bacteria. However some other 
studies suggest that using synergistic drug pair may increase the rate of bacterial evolution 
(Chait, et al. 2007; Hegreness and Kishony 2007; Michel, et al. 2008).  
 
Our study aims systematic exploration of antibiotic resistance in order to understand 
genetic reason behind this problem and find a possible path for resistant mechanism. 
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2 Methods 
 
2.1 M9 Minimal Media  
Minimal Media contains only minimal amount of nutrient that bacteria needs. For 1-liter 
M9 Minimal media; 11.28 mg M9 salt has been dissolved in 860ml distilled water and 
autoclaved at 121 C for 15 minutes. Then 40ml, 25X sterile glucose solution, 100ml, 10X 
sterile amicase solution, 2ml CaCl and 100ul MgS4 added in to M9 salt.  
In order to make 25X Glucose, 50gr Glucose has been dissolved in 500ml distilled water 
and autoclaved for 15 minutes. 
 
In order to make 10X Amicase, 10gr amicase has been dissolved in 500ml-distilled water. 
Amicase may be denaturate in autoclave so filter sterilization has been applied for 
sterilization. 
2.2 Evolution of Bacterial Strains 
At first MG1655 Escherichia coli has been spread on to agar plate and incubate at 30 C for 
16 hours. Single colony obtained from agar plate and has been growth at minimal media at 
30 C for 24 hours.  
Minimal inhibitory concentration (MIC) of Escherichia coli in different antibiotics has 
been determined by following method. In 96-well plate, antibiotic concentration has been 
logarithmically decreased in each 10 well. Each well has half concentration of its left 
neighbor well. After antibiotics in minimal media added in to plate, bacteria has been added 
in to each well. Plate has been put in to shaker in the incubator for 24 hours. After 24 hours, 
OD measurement has been done by using Tecan. The lowest concentration that has no 
growth is MIC 
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22 different antibiotics have been selected. MIC of each antibiotic has been determined. 
MG1655 strain has been exposed to antibiotics separately, with 2 biological replicas, with 2 
different strategies for each drug.  
First day drug concentration have been prepared in 6 culture tube with 3ml minimal media 
in it. First tube has one eight of MIC of drug. Second tube has one four MIC, third has half 
MIC, and others has higher concentration accordingly. Then bacteria have been added, as 
final OD was 0.0001. Then culture tubes placed in to incubator with shaker for ~22 hours. 4 
replicates have been done at first day.  
At second day, growth can be observed at first three concentration tubes. Growing cultures 
observed by visual examination or measured by spectrometer if the growth was not clear on 
eyes. Starting from second day we evolved populations as two different strategies.  Two 
isogenic population evolved under strong selection, other two population evolved under 
mild selection (Figure 2-1). 
Strong selection means that cells were taken from half MIC concentration. For second day 
we made new concentration gradient, this time the lowest concentration tube has half MIC 
of drug.  So each day we are expecting better survival since bacteria exposed high amount 
of drug and survived. 
Mild selection means that cells were taken from one eight MIC. Which means that we 
select bacteria from one four lower concentration of drug comparing to strong selection. 
Again taken concentration will be the lowest concentration tube for second day. 
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Figure 2-1: Evolution experiment in liquid culture under strong selection. Bacterial 
populations were grown in several tubes with increased drug concentrations that span the 
expected minimal inhibitory concentration (MIC) of the population. Populations were 
grown for ~22 hours and the populations surviving in the highest drug concentration were 
transferred to new culture vials (yielding 60X dilution, 6-7 generations per day if new 
mutants do not appear) with increasing drug concentrations. 
 
The minimum drug concentration that inhibited growth (ODfinal< 0.1) was daily recorded 
as MIC of the population (Table 3.1). At the end of each day 30ul bacteria taken from 
growth culture and transferred fresh media tubes with different antibiotic concentration.  
This experiment was made for 21 days with 22 different antibiotics. Each antibiotic has two 
different strategies with two replicas, so we had 88 different populations (Figure 2-1). 
At the ends of 21 days, each population MIC shifted higher concentration comparing to 
wild type.  
On a daily basis, 1 ml of cells were frozen and stored at −80°C in 15% glycerol for further 
characterization. 
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As a negative control wild type Escherichia coli exposed to minimal media without 
antibiotic for 21 days.  
2.3 Selection of Representative Colony 
 
Mixed cultures of 21st day of each drug were spread on agar plate in order to isolate single 
colonies. 10 single colony isolated for each replica, 40 colony isolated for a single drug. 
MIC values determined for each single colonies. . Resistance levels of these colonies did 
not show much variations in their MIC values comparing with population MIC, therefore, 
one colony from all evolved populations were assigned as representative colonies to carry 
out all future genotyping and phenotyping experiments.  
 
Each representative colony named according to drug name, selection strength (strong or 
mild) and replica order. For example; AMP-S-1 means Ampicillin strong number 1.  
2.4 Phenotypic Characterization  
88 representative colonies has been growth separately in minimal media and placed in to 96 
well plates with glycerol. This master plate used for our cross-resistance experiments.  
For cross-resistance experiments 96 well plates prepared with different drug concentration 
for each drug. At least ten different drug concentration 96 well plates were prepared. Drug 
concentration of these plates ranged from drug free to the highest concentration that we can 
dissolve in growth medium Drug concentrations across plates were diluted by a factor of 
101/2 ([drug]n−1 = 101/2× [drug]n). However if the colony’s resistance level is not very 
high comparing to wilt type, in that case a dilution factor of 21/2 was used in order to 
observe more delicate range.  
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After concentration gradient plate with 150ul volume of minimal media was prepared, 
colonies from master plate transferred in to those 96 well plates with antibiotic by using 96-
pinner (V&P Scientific) and were grown for 22 hours with rapid shaking at 30°C. 
 
Final optical densities of the cells were measured using a plate reader (Tecan M200). 
Phenotyping experiments were performed in duplicates for every drug and the mean values 
of these measurements were used for MIC calculations. Background corrected ODfinal 
reads from phenotyping experiments were used to calculate the MIC values of the evolved 
strains. We calculated mean ODfinal values for every strain in every drug concentration we 
used. The MIC values were calculated by interpolating the drug concentrations 
corresponding to mean ODfinal reads corresponding to 0.03.  
 
2.5 Constructing Cross-resistance Networks 
MIC observation experiment applied for each resistance strain against 22 different 
antibiotics by using master plate, as described above. MIC values saved and normalized for 
analysis and building cross-resistance network. Those values then converted to -1, 0, 1, 
respectively antibiotic sensitivity, no change in resistance, and antibiotic resistance. For 
both strongly selected and mildly selected strains, strains are grouped according to drug 
classes and their cross-resistance frequencies (fCR) and antibiotic susceptibility frequencies 
(fAS) against each drug class are calculated. Moreover, the mean cross-resistance (0  CR  
1; 1 being the strongest possible resistance) and antibiotic susceptibility (-1  AS  0; -1 
being 20 fold less resistance compared to the wild type ancestor) values are calculated for 
each cluster.  A seven by seven matrix has been created(Figure 3-5) with frequency and 
cross-resistance (or antibiotic sensitivity) values for strongly selected (panels on the left) 
and mildly selected (panels on the right) strains. The 22 by 88 trinary matrix is then 
randomly shuffled for 10
5
 times and the actual fCRand fASvalues for each group is recorded 
(histograms in panels). Finally, we calculated the probability (p) of randomly getting a 
frequency higher than the actual fCRand fASvalues. We consider the phenotypic changes 
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within clusters which have p values less than 0.05 as significant and score these interactions 
as increased cross-resistance or increased antibiotic susceptibility. 
2.6 Genotypic Characterization 
In order to understand genetic changes and mutations in the evolved strains bacterial cells 
were genotyped by Illumina whole genome sequencing using a HiSeq platform. Cells 
prepared for sequencing in agar stabs and were submitted to Genewiz Incorporation for 
sequencing service. Service from Genewiz included genomic DNA extraction, library 
preparation, multiplexing, sequencing, and data delivery. Sequencing was performed on the 
Illumina HiSeq2000 platform, in a 2x100bp paired end configuration, with at least 100X 
coverage for each sample. We aligned resulting reads onto the MG1655 reference 
chromosome (NC_000913.2) using the Bowtie 2 toolkit (Langmead and Salzberg 2012).  
Aligned sequences were analyzed for genetic changes by using SAMtools and BRESEQ 
software (Barrick et al., 2009; Li et al., 2009). Both tools gave similar results for finding 
SNPs, however BRESEQ is better for finding insertions and deletions. If there is detected 
mutation by only one tool, visual inspection has been used to confirm the mutation. 
Six strains have been sequenced twice in order to confirm accuracy of sequencing.  
MG1655 wild type bacteria also sequenced to examine if there is contamination during 
experiment.  There was no contamination between species however we wanted to make 
sure if there is any contamination between our selected colonies, so that we compared all 
genetic changes in all strains. All strains have different mutations accept TMP-M-1 and 
TMP-S-2. However the mutations, that both have, are pathway specific folA mutation, 
which are expected to observed in TMP resistant bacteria.  
Cefoxitin resistant strains; CEF-S1 and CEF-S-2 interestingly have more then 200 
mutations. It requires deep and separate analyze to understand all those mutations. 
Therefore we exclude their mutation, during analyzing our data.  
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2.7 Functional Classification 
In order to understand and analyzed mutations, we used EcoCyc gene database for the 
bacterium Escherichia coli K-12 MG1655. EcoCyc we giving properities of that gene, and 
according to information on EcoCyc we have decided wheter the mutation on that gene is 
pathways specific or not. Pathway specific means that; such mutations are directly effect of 
mechanism of the drug.  
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3 Results 
3.1 Evolution Experiment 
First part of the project was evolving wilt type Escherichia coli against 22 different 
antibiotics. For each antibiotic we had 2 different evolution strategies: strong selection, 
mild selection. For each selection we made 2 biological replicas. At the end of 21 days, we 
had 88 different strains that are resistant to 22 different antibiotics (Figure 3-1). 
Concentration of drug increased day by day if necessary according to our method. However 
Fusidic Acid has been reached its maximum solubility (3200ug/ml), at day fifth, so Fusidic 
Acid concentration remained say for the rest of experiment.  
 
 
Table 3-1: List of all drugs that have been used in project. Drug names and abbreviations, 
solvent, MIC values for wild type Escherichia Coli MG1655, maximum dose that used in 
experiment, daily clinical dose average (taken from http://www.globalrph.com), higher 
MIC reported in EUCAST, mechanism of action and phenotypic effect: bacteriostatic or 
bactericidal. (Oz & Guvenek & Yildiz 2014) 
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Strong selections and mild selections act differently in some cases, such as; Tobramycin, 
Kanamycin, Spectinomycin, Cefoxitin, Ciprofloxacin and Nitrofurantoin. For those drugs 
resistance level of strong selection and mild selection are far from each other. However in 
other drugs, resistance level of strong selection and mild selection are same or very close 
with each other.  
Resistance pathway of each strain may show differences, both phenotypically and 
genotypically. When we look at Spectinomycin strong selection strains and mild selection 
strains get very different level of resistance. However two replicates of strong selection 
strain act similar.  
When we look at Streptomycin both 4 strains resistance levels are same in the end, however 
their behaviors are different than each other.  
We can say that strongly selected strains have relatively higher resistance level. In some 
cases strong and mild selection strains have same resistance level. But there is no case such, 
mild resistant strains have higher resistance level. 
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Figure 3-1: MIC level of resistance strains. Daily-recorded MIC values of resistant strains 
strongly selected (red circle and red triangle) and mildly selected strains( black circle and 
clack triangle) for each drug. X axis stands for days and Y axis stands for minimum 
inhibitory concentration of drug. (Oz & Guvenek & Yildiz 2014) 
 
3.2 Cross-resistance Experiment 
After observing changes in MIC level against corresponding antibiotics, we design a cross-
resistance experiment in order to build a cross-resistance network.  
We expect resistant strains were pleiotropically developed cross-resistance against other 
antibiotics. Our expectation was antibiotics that are in the same class should have 
developed cross-resistance against each other. In order to build this map, we did 
concentration gradient for all 22 drugs in order to calculate MIC level of the resistant 
strains (Methods).  
In this cross-resistance map, we used Mat Lab for visualization. We compared MIC of the 
strain with MIC of wild type.Figure 3-2-A shows MIC of 3 different resistant strains, and 
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wilt type in Chloramphenicol. As it shown Chloramphenicol resistant strain has higher MIC 
(~60 times) then wilt type MIC, as expected. Doxycycline resistant strain also shows higher 
MIC. Doxycycline resistant strain has never been exposed to Chloramphenicol during 
evolution experiment. However a cross resistant occurred in that strain.  
On the other hand, Tobramycin resistant strain sensitivity against Chloramphenicol has 
been decreased, as can be seen in Figure 3-2-A. This was an interesting result. 
Understanding why a strain become even more sensitive then wild type against other drug 
was one of the important questions of this project.  
Finally we build up a cross-resistance map, for all strains (Figure 3-2-B, C). Figure 3-2 B 
shows cross-resistance behavior of strongly selected strains. Figure 3-2-C shows cross-
resistance behavior of mildly selected strains. Similar behaviors can be observed at both 
maps. Red color represents if the strain has at least 3 times higher MIC then wilt type. Blue 
color shows if the strain has at least 3 times lower MIC then wilt types. White colors means 
that strain has same MIC as wilt type.  By looking these maps, we can say that resistance 
behavior is relatively higher in strongly selected strains.  
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Figure 3-2: Cross-resistance measurement of all strains. (A) Representative strains for 
extreme examples. Chloramphenicol resistance of wild type ancestor strain (green circles), 
a strain evolved against doxycycline (DOX-S-2, orange triangles), a strain evolved against 
chloramphenicol (CHL-S-2, red circles), and a strain against kanamycin (TOB-S-2, blue 
circles) were measured. (B) Cross-resistance map of strains evolved under strong selection. 
(C) Cross-resistance map of strains evolved under mild selection. (Oz & Guvenek & Yildiz 
2014) 
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In order to understand behavior of a antibiotic class against other classes we built a cross-
resistance network for both strong and mild selection. (Figure 3-3)  
Figure 3-3-A shows resistance/sensitivity behavior with in the antibiotic classes and if there 
is general trend between classes. Again red represent increased cross-resistance and blue 
represent increased cross sensitivity, and intensity of the color in a line represents the 
frequency of increased cross-resistance or antibiotic susceptibility against a drug or drug 
class.  
Increased cross-resistance is very common within the antibiotic class. Almost all of the 
antibiotic resistant strains gain resistant to other antibiotic in its own class, although, there 
were two exceptions of this trend. Such interaction cannot be observed for Folic acid 
synthesis inhibitors and Ribosomal 30S Inhibitors.  
Very important observation of this project is increased sensitivity of Aminoglycoside 
resistant strains against other antibiotic classes. On both Figure 3-2and Figure 3-3we 
observed that resistant strains of Aminoglycoside (Tob, Str, Amk, Kan) have increased 
resistance against each other, but increased sensitivity against other drug classes. This 
observation on their phenotype led us to discover a specific gene mutation, when we 
analyze the sequencing results. Another thing is, addition to this unique behavior of 
aminoglycoside, none of the other drug classes developed resistance against 
aminoglycoside.  
Folic acid synthesis inhibitors were another interesting observation of this study. As 
mentioned above, they didn’t developed resistance within the group. Also they didn’t 
developed resistance against other drugs from other classes. So we can say that their 
resistance mechanisms can be an independent mechanism.  
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Figure 3-3: Cros resistance network. (A) Network for strains evolved under strong 
selection. (B) Network for strains evolved under mild selection. Red lines represent cross-
resistance and blue lines represent sensitivity. Resistance or sensitivity activity of a strain 
against other drugs in its class is shown in each circle. Resistance or sensitivity of all strains 
in one class against other drug classes are shown between circles. (Oz & Guvenek & Yildiz 
2014) 
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Figure 3-4: For every evolved strain, we calculated direct-resistance values and mean cross-
resistance values. Using these values we calculated Pearson’s linear correlation coefficients 
and p values separately for (left panel) strongly selected strains (R=0.28, p=0.064), (middle 
panel) mildly selected strains (R=0.047, p=0.76), and (right panel) strongly selected and 
mildly selected strains together (R=0.23, p=0.033). Direct-resistance values are plotted 
against mean cross-resistance values (black and red circles are used for mildly and strongly 
selected strains respectively) for all 88 evolved strains and blue lines show the best linear 
fit. (Oz & Guvenek & Yildiz 2014) 
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Figure 3-5: Frequency and cross-resistance levels of strains evolved against drug classes. 
Normalized values of cross-resistance converted to -1, 0, 1, respectively antibiotic 
sensitivity, no change in resistance, and antibiotic resistance. For both strongly selected and 
mildly selected strains, strains are grouped according to drug classes and their cross-
resistance frequencies (fCR) and antibiotic susceptibility frequencies (fAS) against each 
drug class are calculated. Moreover, the mean cross-resistance (0 ≤ CR ≤ 1; 1 being the 
strongest possible resistance) and antibiotic susceptibility (-1 ≤ AS ≤ 0; -1 being 20 fold 
less resistance compared to the wild type ancestor) values are calculated for each cluster.  A 
seven by seven matrix has been createdwith frequency and cross-resistance (or antibiotic 
sensitivity) values for strongly selected (panels on the left) and mildly selected (panels on 
the right) strains. The 22 by 88 trinary matrix is then randomly shuffled for 105 times and 
the actual fCR and fAS values for each group is recorded (histograms in panels). Finally, 
we calculated the probability (p) of randomly getting a frequency higher than the actual 
fCR and fAS values. We consider the phenotypic changes within clusters which have p 
values less than 0.05 as significant and score these interactions as increased cross-resistance 
or increased antibiotic susceptibility. (Oz & Guvenek & Yildiz 2014) 
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3.3 Genotypic Characterization 
In order to understand genetic changes on evolved strains, 88 evolved strains has been 
sequenced. All the genetic changes can are available on Appendix A. In addition to 88 
strains, we sequenced two wild type, 4 replicas of randomly selected colonies, and 2 wild 
type strains who has been growth in minimal media for 21 days, without any antibiotic.  
Two strains that exposed nothing but minimal media have same genetic changes. There 
were deletions of 82 base pair in the pyrE-rph operon in both strains. In order to understand 
if that mutation has any effect on bacteria we compared growth rates of all 88 evolved 
strains, media adapted 2 strains, and wilt type MG1655. Doubling time for MG1655 was 
70±4 minutes (mean ± standard deviation), as well as the doubling time for minimal media 
adapted strain was 483 minutes, which means that pyrE-rphdeletion causes an elevation in 
growth rate. This mutation was previously reported as a minimal media adaptation related 
mutation(Conrad, et al. 2009). This result led us to understand changes in growth rate in 
some resistant strains.  
On Figure 3-6 green line represent growth rate of MG1655, and blue line represent growth 
rate of media adapted strains. Without knowing the effect of pyrE-rphdeletion it would be 
difficult to understand the strains have better growth rate then wild type.  Mutations in the 
rph-pyrEoperon were observed in 29 of the resistant strains and majority of these strains 
(24 out of 29) were growing significantly faster (Figure 3-6, p<0.05, Wilcoxon rank-sum 
test) than the wild type ancestor strain. Again, majority of fast growing strains were mildly 
selected strains (20 out of 24).  
There were 17 strains that have significantly lower growth rate (twelve strongly selected 
and five mildly selected. When we compared growth rate of strongly selected and mildly 
selected strains, average growth rate for the strains evolved under strong selection was 
71±16 minutes whereas the average growth rate for the strains evolved under mild selection 
was 59±12 minutes. 
 31 
 
Figure 3-6: Growth rate of each evolved strains in 30°C in M9 minimal medium. Red color 
represents strong selection strains and black color represents mildly selected strains. Green 
rectangle represent mean growth rate of wild type ancestor MG1655 and blue rectangle 
represents strains evolved in minimal media for 21 days. Error bars show the standard 
deviations of 6 growth rate measurements per strain. Upward triangle used for strains that 
growth rate is higher than ancestor strains and downward triangle used for strains that 
growth rate is lower than ancestor strains. Filled markers represent strains that carry 
deletions of 82 base pair in the pyrE-rph operon. (Oz & Guvenek & Yildiz 2014) 
 
All the mutations in all strains are provided in Appendix A. We observed total 215 
mutations, 113 of them were SNPs and 102 of them were indels. In order to better 
understand those mutations, mutations were grouped according to their antibiotic class 
inFigure 3-7. In Figure 3-7 the genetic changes found in strains has been shown by radially 
distributing mutations on circular plots according to mutations’ locations on E. coli 
reference genome. Indels has shown as filled red and black triangles and SNPs has shown 
as filled red and black circles. Strongly selected strains had 124 mutations in total (111 in 
coding regions, 13 in intergenic regions) and mildly selected strains had 91 mutations (83 
in coding regions, 8 in intergenic regions).  
Two of the strains (CEF-S-1 and CEF-S-2) have 558 mutations in total, so they were 
excluded from all analyses. Out of 558 mutations 139 of them were synonymous mutations.  
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According to drug’s mechanism of action, we classified mutations in to two; pathway 
specific and off pathway mutation. In Figure 3-7pathway specific mutations are shown in 
blue color. Outer red circle represents mutations of strains evolved under strong selection 
and inner black circle represents mutation evolved under mild selection. If a mutation has 
been seen more than once, it can also be detected on Figure 3-7. 
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Figure 3-7: Mutations found in strains evolved against a drug class under strong selection (outer red circle) and mild selection 
(inner black circle) are shown with filled red and black markers respectively. SNPs are shown with filled circles and 
insertions/deletions are shown with filled triangles. Mutated genes’ names are printed using standard annotations; however 
mutations are printed as “unknown” if there are no annotated genes found in literature. Pathway-specific mutations are printed in 
blue. (A) Mutations found in strains evolved against antibiotics with multiple mechanisms (nitrofurontain). (B) Mutations found 
in strains evolved against 50S ribosomal inhibitors. (C) Mutations found in strains evolved againstaminoglycosides. TheTrkH 
gene, which is mutated in five aminoglycoside resistant strains, is shown with a magenta arrow. (D) Mutations found in strains 
evolved against 30S ribosomal inhibitors. (E) Mutations found in strains evolved against beta-lactams. (F) Mutations found in 
strains evolved against DNA gyrase inhibitors. (G) Mutations found in strains evolved against folic acid synthesis inhibitors. (Oz 
& Guvenek & Yildiz 2014) 
G 
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In order to understand our results better, we made Table 3.2, which allows us to see 
mutations that belong to a specific drug group. However Table 3.2 only contains mutations 
that occur more than one times.  In Table 2 pathway specific and off pathway mutation for 
each drug can be seen. For all of the drugs we used in evolution experiments (except 
chloramphenicol, doxycycline and tetracycline), we were able to identify several pathway-
specific gene mutations in evolved strains. Mutated gene names marked with asterisks are 
genes that previously reported in literature to be involved antibiotic resistance studies.  
For example SNP in folA has been reported to be involved with trimethoprim resistance in 
Escherichia Coli (Keith Miller 2004).  
We conclude that since mutations in Table 2 has been observed more than one time, more 
than one strain, these entire mutations can ben related with drug resistance.  
Off pathway mutations were interesting observation of this study. They are obviously 
related with drug resistance behavior of our resistance strains. There are 71 off pathway 
mutation in strongly selected strains and 38 off pathway mutation in mildly selected strains 
(Figure 3.8). Again mutations that previously reported in literature to be involved antibiotic 
resistance studies have been shown with asterisk on the gene name.  
Number of mutation belonging to major pathways of strong selection and mild selection for 
each class has been demonstrated in Figure 3-8-A. Figure 3-8-B shows number of pathways 
specific mutations accordingly.  
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Figure 3-8: Effect of selection strength on genetic diversity. (A) Number of mutation 
belongs major cellular pathways in strongly selected (S) and mildly (M) selected strains. 
Strains clustered according to major antibiotic classes. (B) Pathway specific mutations per 
classes for strongly selected (S), and mildly selected (M) strains. (C) trkH mutations and 
drug sensitivity on aminoglycosides. Blue color weight of bars indicated strength of 
sensitivity. (Oz & Guvenek & Yildiz 2014) 
.  
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One of the most important finding of this study was aminoglycoside resistant strains 
behavior against other drugs. Aminoglycoside resistant strains were resistant to other drugs 
in their class but susceptible to other drugs from other class. We found out that six of the 
eight aminoglycoside resistant strains have mutation in trkH gene (Figure 3.8-B).  
 
Table 3-2: Drug classes, drugs used for selection, mutated pathway-specific genes, mutated 
off-pathway genes.  Genes that are reported in literature to be related to antibiotic resistance 
are marked with asterisks. (Oz & Guvenek & Yildiz 2014) 
 
3.4 Mutants Behavior on Different Temperature 
 
Slow growth in mutant strains has been observed in previous studies before (Blackburn and 
Davies 1994). In this project some resistant strains such as: AMK-S1, KAN-S-2, ERY-S-1, 
CHL-S1,S-2 have significantly slower growth rate comparing to their ancestor wild type. 
Slower growth rate in resistant strains has been observed before, even when the stress 
factor has been remove, resistant bacteria turn back to be sensitive because of cost-benefit 
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optimization (Dekel and Alon 2005). The interesting observation of this study was some 
strains were growing better than its ancestor (Figure 3.6). In order to understand those fast 
growing strains we first tested all resistant strains in different temperature. Resistant strains 
and their wild type ancestor has been growth at 9 different temperature between 28 °C and 
42 °C (Figure 3.9).  For almost all strains 37 °C were optimal temperature except NIT-S-1 
(Figure 3.10). NIT S-1 was an interesting strain that cannot grow temperatures above 37 
°C. KAN-M-1 growth rate was also dramatically decreased temperatures above 39 °C. All 
these different behaviors at different temperatures should be investigated more in future 
studies.  
About faster growing strains, we observed rph-pyrE mutations majority of those strains. 
We sequenced two strains that were propagated for 28 days in the absence of any 
antibiotics in minimal media, and those two also had deletion on rph-pyrE operon. And 
those media adapted strains also grow faster than its ancestor. We come up with a 
conclusion that this mutation is related with faster growing behavior. In literature pyrE 
previously reported with its relation with minimal media adaptation (Jensen 1993; Conrad, 
et al. 2009). Considering our result with Jensen’s study, deletion in rph-pyrE operon should 
be related with our observation. 
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Figure 3-9: Effect of selection strength on growth rate at different temperatures. (A) Mean 
of growth rates. Red marker indicates strongly selected strains; black marker indicates 
mildly selected strains and green lines indicates growth rate of wild type. (B) Mean of 
growth rates in different temperatures. Red marker indicates strongly selected strains; black 
marker indicates mildly selected strains; green marker indicates growth rate of wild type 
and blue marker indicates mean of all strains.  
 
Figure 3-10: Growth rate of all strains at different temperatures between 28 °C and 42 oC. 
Each circle represents growth rate of different temperatures. 
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4 Discussion 
In this study we accomplish systematic study of antibiotic resistance of Escherichia Coli. 
We pointed out the affect of selection strength as an important factor on bacterial evolution 
resistance mechanism. We combined phenotypic observation with genotypic observation 
and revealed important facts about evolutionary mechanisms. Bacteria developed resistance 
under stronger selection developed cross-resistance against several other drugs. Bacteria 
developed resistance under mild selection also developed cross-resistance, however that 
was significantly lower comparing to strong selection strains.  
Strength selection has important effect on genetic diversity. Strong selection bacteria have 
more mutation in both number and diversity. Strongly selected strains have more pathway 
specific mutations comparing to mild selection. However pathway specific mutation and 
probably multidrug resistance gene mutation cost is higher, so fitness is lower. If mutated 
genes are important genes that effect cellular machinery, changes have huge fitness cost. 
An example of higher genetic diversity in strongly selected strain is aminoglycosides. 
Strongly selected aminoglycosides have 32 mutations in total and 13 of them were pathway 
specific mutation. Whereas mildly selected aminoglycosides have 22 mutations in total and 
only 4 of them were pathway specific. On the other hand folic acid synthesis inhibitors 
does not show such diversity. Strongly selected strains and mildly selected strains almost 
have same number of mutation. However when we look at the evolutionary experiment 
(Figure 3.1) we saw that evolutionary pathway of strongly selected strains and mildly 
selected strains are not very different on this group.  Another interesting observation about 
folic acid synthesis inhibitors that TMP-S-2 and TMP-M-1 have exactly same mutations, 
and all strains have mutation in folA gene. This result in not surprising since pathway 
specific DHFR mutation has been observed in TMP resistance strains in previous studies 
(Toprak, et al. 2012). 
Collateral sensitivity of aminoglycoside was another important discovery of this study. 
Recently another research group also discovered same collateral sensitivity of 
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aminoglycosides(Imamovic and Sommer 2013). In Imamovic’s study they applied strong 
selection in order to evolved bacteria. Similarity between Imamovic’s work and this project 
is not surprising since we observed stronger collateral sensitivity in strongly selected 
strains. They demonstrate phenotype of collateral sensitivity but their study was lack of 
genetic data. Meanwhile another group Lazar et al evolved Escherichia Coli against several 
antibiotics including aminoglycosides and sequenced resistant strain and discovered trkH 
mutation behind this sensitivity, similar to our findings(Lazar, et al. 2013). In addition to 
their findings we contribute these finding by studying selection strength. This collateral 
sensitivity can be a new strategy to minimize antibiotic resistance. In future research 
combined therapy of aminoglycoside with antibiotics that are not member of 
aminoglycosides should be tested.   
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5 Conclusions 
In this study we pointed out a hidden factor in antibiotic resistance, which is selection 
strength. We concluded that selection strength is an important parameter that affects 
complexity of resistance evolution. We observed that population evolved in high 
concentration of drug acquired significantly higher cross-resistance. This result can lead 
new perspective on evolution of resistance, since physicians prefer to use highest 
concentration of drug in order to minimize cross-resistance. High concentration is useful 
the drug kills all the population, however in case of survival, bacteria will develop stronger 
cross-resistance.   
To minimize cross-resistance, cross sensitivity aminoglycoside can be used in clinic, 
although it requires further investigation. During the treatment combination therapy can be 
used for patient, not because synergistic effect of drugs, but because cross sensitivity 
properties of aminoglycosides. During antibiotic treatment in specific days aminoglycoside 
can be used to slow down the resistance. This kind of study has not been done yet, however 
it may give promising result for resistance evolution.  
Our study highlighted important and newly discovered facts about resistance evolution and 
further studies about selection strength and cross sensitivity will give better understanding 
about this area. 
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7 Appendices 
7.1 Appendix A  
Genetic changes found in all sequenced strains except CEF-S-1 and CEF-S-2.Sequence ID, 
strain ID, drug class used for selection, genome position of the mutation, nucleotide 
change, annotation of the mutation, mutated gene(s), description of the mutated gene(s), 
gene function, selection strength, exclusivity (exclusive: mutation found in only mildly 
selected or strongly selected strains, common: mutation found in both mildly selected and 
strongly selected strains), pathway-specifity 
 51 
  
 52 
 
 53 
 
 54 
 
 55 
 
 56 
 
 57 
 
 58 
 
 59 
 
 60 
 
 61 
 
 62 
 
 63 
 
 64 
 
 65 
7.2 Appendix B 
 Daily MIC values of 88 strains. 
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7.3 Appendix C 
MIC values of all evolved strains in 22 antibiotics. 
 
ug/ml PIP(M(1 PIP(M(2 AMP(S(1 AMP(S(2 AMP(M(1 AMP(M(2 CEF(S(1 CEF(S(2 CEF(M(1 CEF(M(2 NAL(S(1 NAL(S(2 NAL(M(1 NAL(M(2 LOM(S(1 LOM(S(2 LOM(M(1 LOM(M(2 CIP(S(1 CIP(S(2 CIP(M(1 CIP(M(2 SMO(S(1 SMO(S(2 SMO(M(1
Chloramphenicol 6.667 20.307 23.501 27.882 20.226 6.967 58.800 56.626 20.442 18.488 6.137 5.974 5.850 6.112 57.366 178.632 6.066 6.145 9.128 21.882 19.691 6.110 6.104 5.968 5.964
Clindamycin 347.775 318.113 99.897 99.578 103.921 104.430 89.268 114.298 357.811 309.778 99.583 100.906 99.854 99.507 384.900 970.427 103.872 100.765 299.902 101.972 330.471 97.516 97.859 89.303 98.889
Erythromycin 174.461 183.882 62.445 61.311 61.136 65.290 58.663 62.661 60.504 59.760 71.138 65.413 73.530 71.898 226.625 590.691 76.320 81.164 72.473 183.120 67.036 66.724 76.777 91.983 73.044
Spiramycin 624.260 624.333 245.563 251.136 245.322 232.372 190.412 195.363 254.633 170.625 275.913 255.745 244.256 242.507 657.961 612.716 282.309 269.433 229.006 601.920 597.329 634.942 277.421 253.989 242.345
FusidicJAcid 1107.103 1057.580 609.960 586.701 468.086 459.864 264.316 273.835 516.756 505.422 527.236 545.454 915.795 866.241 1707.203 1237.359 1060.437 935.379 1554.821 1727.025 991.876 917.700 782.868 571.191 491.998
Amikacin 14.817 15.119 14.902 4.565 14.568 4.878 14.600 19.364 14.997 14.579 14.751 14.398 14.822 14.056 5.804 4.570 14.384 15.050 15.462 14.894 14.983 14.993 5.713 14.659 13.321
Tobramycin 2.842 2.713 2.974 0.961 2.906 2.711 2.909 3.109 2.995 2.967 0.999 1.036 1.236 1.205 0.962 0.961 2.824 2.771 2.784 1.072 2.936 2.968 0.975 1.177 1.145
Streptomycin 15.435 14.864 14.485 4.793 14.748 14.208 16.128 44.541 44.500 14.838 14.919 14.872 14.810 15.163 14.562 14.003 15.018 15.006 15.009 14.891 15.519 15.082 14.968 14.826 14.776
Kanamycin 11.599 11.517 11.733 3.761 11.740 35.403 12.665 35.789 36.503 31.986 11.578 11.615 11.334 13.144 11.349 10.227 11.747 11.559 11.517 11.581 12.738 11.575 11.363 11.678 11.600
Tetracycline 2.533 3.530 3.505 3.449 2.600 2.479 7.719 10.385 3.460 3.580 1.220 1.227 1.736 1.216 3.619 3.572 1.307 1.298 3.548 3.569 2.534 3.454 1.812 1.296 1.200
Doxycycline 2.339 2.292 0.822 0.804 0.787 0.773 4.225 6.988 1.177 1.606 1.456 1.642 1.598 1.651 7.326 4.792 2.027 2.084 3.446 3.667 1.785 2.007 2.598 1.197 1.168
Spectinomycin 73.249 69.687 63200.000 57.049 63200.000 87.885 58.405 70.825 1043.225 157.023 59.374 59.558 58.700 58.271 59.857 54.345 59.337 60.026 65.368 60.199 170.037 162.346 58.866 61.464 60.710
Piperacillin 3.929 5.525 11.988 5.970 3.954 5.531 2.930 7.677 5.489 5.453 2.079 1.841 2.210 2.364 9.180 11.884 2.761 2.707 5.320 5.526 4.071 5.406 2.860 1.761 1.390
Ampicillin 9.735 19.823 82.476 82.502 30.347 27.792 115.130 120.000 56.532 39.559 13.713 4.791 4.864 3.673 14.202 30.968 28.129 28.429 7.266 15.406 13.696 13.417 6.386 6.732 6.464
Cefoxitin 5.910 18.351 58.029 58.069 207.310 18.089 4256.058 1758.138 222.509 519.306 6.287 105.702 7.083 16.242 17.126 23.817 1.901 2.594 22.852 16.322 15.210 34.762 1.971 1.932 1.873
NalidixicJacid 7.647 7.689 7.770 7.821 8.033 7.700 214.130 221.810 7.624 7.810 790.000 790.000 790.000 790.000 790.000 250.067 790.000 790.000 790.000 790.000 790.000 234.348 31.873 73.636 74.698
Lomefloxacin 0.311 0.310 0.308 0.294 0.299 0.318 0.346 0.367 0.222 0.886 3.151 3.193 3.209 3.000 9.687 9.527 3.346 3.255 9.618 9.875 3.261 3.154 0.342 0.312 0.299
Ciprofloxacin 0.015 0.047 0.044 0.040 0.046 0.047 0.040 0.039 0.013 0.015 1.308 1.324 1.258 0.508 1.600 1.536 1.383 1.359 1.600 1.600 1.513 1.513 0.016 0.015 0.017
Sulfamonomethoxine 1.711 1.723 1.680 1.639 1.654 0.924 25.472 17.135 21.944 3.984 1.443 1.522 1.388 1.517 10.436 5.824 1.741 1.484 1.806 1.776 1.708 1.761 7.612 8.656 4.184
Trimethoprim 358.287 4.462 4.001 3.781 3.654 3.681 404.208 31.329 363.161 4.244 7.234 4.840 7.409 6.642 41.146 13.556 5.258 13.620 19.685 22.071 7.326 14.705 15.200 5.252 12.416
Sulfamethoxazol 2.470 2.407 1.890 1.856 1.662 1.560 20.541 2.976 9.519 3.030 2.362 2.279 2.175 2.247 2.678 2.607 2.374 2.366 2.367 2.397 2.461 2.994 2.967 2.706 2.667
Nitrofurantoin 5.083 12.491 4.642 4.548 4.574 4.492 4.859 13.462 13.836 15.297 4.673 4.664 4.644 4.671 12.093 12.829 4.699 4.932 17.000 13.519 14.405 14.790 5.275 14.200 12.718
